Cardiogen vs CJC-1295 with DAC
Moderate Research vs Well Studied
synergistic Mechanism-based · 47% Cardiogen and CJC-1295 with DAC work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Cardiogen CJC-1295 with DAC
Weight 460 Da 3,647.28 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes 6-8 days
Chain 4 amino acids 30 amino acids
Type Tetrapeptide bioregulator GHRH analog with DAC
Key Benefits
Cardiogen
01 Supports cardiac tissue repair and regeneration
02 Regulates cardiovascular gene expression
03 Improves myocardial function
04 May support post-cardiac event recovery
05 Epigenetic mechanism for targeted action
06 Works at DNA/nuclear level
07 Part of comprehensive anti-aging protocols
08 Well-researched Khavinson peptide
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dosing Protocols
Cardiogen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Side Effects
Cardiogen
Generally well-tolerated
Minimal side effects reported
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Contraindications
Active cardiac emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Diabetes history
Cancer history
Predisposed sleep apnea
Research Evidence
Cardiogen CJC-1295 with DAC
Status Moderate Research Well Studied
References 3 studies 4 studies
Latest — 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.